Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

RCT (n=1033) found baricitinib+remdesivir was superior to remdesivir in reducing recovery time (median time to recovery 7 vs 8 days; rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P=0.03) with clinical improvement in those receiving high-flow oxygen (1.51; 1.10 to 1.6).

New England Journal of Medicine